http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0620732-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
| filingDate | 1993-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb6de564e0b42ed785cf3e9076731fd8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28d4bec3aeee77d2cfe14eff50748a3a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a62d9e27a534a44dc3ec8cb4aad4a07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22cbce8c477f3d5802189fcb11ba68d1 |
| publicationDate | 1994-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0620732-A1 |
| titleOfInvention | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| abstract | A method of treating a mammal comprising administering to said mammal an effective amount, in order to produce a desired therapeutic effect, of a compound selected from the group represented by the constituents of formula (1), as well as their acid addition salts and pharmaceutically acceptable mixtures thereof, wherein R1 and R4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; R2 are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or together represent oxo; R3 are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or together represent oxo; the 2-imidazoline-2-ilamino group can be found in any of the positions 5-, 6-, 7- or 8- of the quinoxaline nucleus; each of R5, R6 and R7 is located in one of the remaining positions 5-, 6-, 7- or 8- of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Said compounds, when administered to a mammal, produce desired therapeutic effects, such as reduction of peripheral pain, anesthesia of the central nervous system, constriction of one or more blood vessels, reduction or prevention of '' at least one effect of ischemia, decongestion of one or more nasal passages, as well as the reduction of at least one effect of an inflammatory disease. |
| priorityDate | 1992-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 146.